HK1226440A1 - Cmv疫苗 - Google Patents

Cmv疫苗

Info

Publication number
HK1226440A1
HK1226440A1 HK16114631A HK16114631A HK1226440A1 HK 1226440 A1 HK1226440 A1 HK 1226440A1 HK 16114631 A HK16114631 A HK 16114631A HK 16114631 A HK16114631 A HK 16114631A HK 1226440 A1 HK1226440 A1 HK 1226440A1
Authority
HK
Hong Kong
Prior art keywords
cmv vaccines
cmv
vaccines
Prior art date
Application number
HK16114631A
Other languages
English (en)
Inventor
Klaus Orlinger
Karen Lingnau
Thomas Monath
Farshad Guirakhoo
Gerhard Fuhrmann
Katherine Cohen
Vera Baumgartl-Strasser
Andreas Aspöck
Manuela Kainer
Bernhard Brim
Bettina Kiefmann
Elizabeth Watson
Mario Aistleithner
Katharina Bayer
Elsa Mühlbacher
Original Assignee
Hookipa Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Ag filed Critical Hookipa Biotech Ag
Publication of HK1226440A1 publication Critical patent/HK1226440A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16114631A 2013-12-03 2016-12-23 Cmv疫苗 HK1226440A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911135P 2013-12-03 2013-12-03
US201462055699P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
HK1226440A1 true HK1226440A1 (zh) 2017-09-29

Family

ID=52232138

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16114631A HK1226440A1 (zh) 2013-12-03 2016-12-23 Cmv疫苗

Country Status (18)

Country Link
US (3) US10111945B2 (zh)
EP (2) EP3904522A1 (zh)
JP (2) JP6818551B2 (zh)
CN (2) CN105980570B (zh)
AU (2) AU2014359276B2 (zh)
CA (1) CA2932318C (zh)
CY (1) CY1124288T1 (zh)
DK (1) DK3077519T3 (zh)
ES (1) ES2868427T3 (zh)
HK (1) HK1226440A1 (zh)
HR (1) HRP20211015T1 (zh)
HU (1) HUE054579T2 (zh)
LT (1) LT3077519T (zh)
PL (1) PL3077519T3 (zh)
PT (1) PT3077519T (zh)
RS (1) RS61993B1 (zh)
SI (1) SI3077519T1 (zh)
WO (1) WO2015082570A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221475T3 (hr) 2007-12-27 2023-01-06 Universität Zürich Replikacijski defektni vektori arenavirusa
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
PT3077519T (pt) 2013-12-03 2021-05-13 Hookipa Biotech Ag Vacinas contra cmv
AU2015345080B2 (en) 2014-11-13 2022-01-27 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
FI3371316T3 (fi) 2015-11-04 2023-01-13 Rokotteita hepatiitti b -virusta vastaan
CN108697775B (zh) * 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
US11260090B2 (en) 2016-03-08 2022-03-01 University Of Vermont And State Agricultural College Modified arenavirus
KR102574810B1 (ko) 2016-04-15 2023-09-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 습성 연령 관련 황반 변성의 치료를 위한 조성물
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS
EP3534943A2 (en) 2016-11-04 2019-09-11 Hookipa Biotech GmbH Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
BR112019021569A2 (pt) 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
WO2018204080A1 (en) * 2017-05-02 2018-11-08 The Scripps Research Institute Compositions and methods related to arenavirus immunogens
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
WO2020079586A1 (en) * 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CA3121915A1 (en) * 2018-12-10 2020-06-18 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
WO2021089853A1 (en) 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
CN115698298A (zh) * 2020-06-09 2023-02-03 Km生物医薬股份公司 巨细胞病毒的gB与五聚体的融合蛋白和包含该融合蛋白的疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
RU2756557C1 (ru) * 2020-11-02 2021-10-01 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов
EP4291249A2 (en) 2021-02-10 2023-12-20 RegenxBio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
EP4337320A1 (en) 2021-05-13 2024-03-20 Hookipa Biotech GmbH Arenaviruses as vectors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE60116068T2 (de) * 2000-03-21 2006-08-17 Genzyme Corp., Framingham Therapeutische anti-cytomegalovirus verbindungen
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
HRP20221475T3 (hr) * 2007-12-27 2023-01-06 Universität Zürich Replikacijski defektni vektori arenavirusa
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
WO2010148541A1 (zh) * 2009-06-26 2010-12-29 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的胜肽的免疫原组成物及使用方法
AU2011315447A1 (en) * 2010-10-15 2013-05-09 Glaxosmithkline Biologicals S.A. Cytomegalovirus gB antigen
WO2012093340A2 (en) 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
WO2012162428A1 (en) * 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
US11896636B2 (en) * 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
US8834307B2 (en) 2011-10-06 2014-09-16 Kawasaki Jukogyo Kabushiki Kaisha Belt type continuously variable transmission
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
CN104853771A (zh) * 2012-07-06 2015-08-19 诺华股份有限公司 巨细胞病毒蛋白的复合物
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
PT3077519T (pt) 2013-12-03 2021-05-13 Hookipa Biotech Ag Vacinas contra cmv
AU2015345080B2 (en) * 2014-11-13 2022-01-27 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
FI3371316T3 (fi) 2015-11-04 2023-01-13 Rokotteita hepatiitti b -virusta vastaan
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
CA3023599A1 (en) 2016-05-18 2017-11-23 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
EP3534943A2 (en) 2016-11-04 2019-09-11 Hookipa Biotech GmbH Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
WO2021089853A1 (en) 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors

Also Published As

Publication number Publication date
CA2932318C (en) 2023-10-10
EP3077519B1 (en) 2021-03-31
US11554169B2 (en) 2023-01-17
EP3904522A1 (en) 2021-11-03
JP2017503482A (ja) 2017-02-02
HRP20211015T1 (hr) 2021-10-01
WO2015082570A1 (en) 2015-06-11
AU2021202541A1 (en) 2021-05-27
CN105980570B (zh) 2022-06-07
JP2021061848A (ja) 2021-04-22
US20160296619A1 (en) 2016-10-13
SI3077519T1 (sl) 2021-07-30
JP7001807B2 (ja) 2022-02-04
PT3077519T (pt) 2021-05-13
AU2014359276B2 (en) 2021-01-28
PL3077519T3 (pl) 2021-10-18
ES2868427T3 (es) 2021-10-21
US20190247493A1 (en) 2019-08-15
CN115058452A (zh) 2022-09-16
RS61993B1 (sr) 2021-07-30
CY1124288T1 (el) 2022-07-22
CN105980570A (zh) 2016-09-28
EP3077519A1 (en) 2016-10-12
JP6818551B2 (ja) 2021-01-20
WO2015082570A8 (en) 2015-11-26
US20230181725A1 (en) 2023-06-15
HUE054579T2 (hu) 2021-09-28
LT3077519T (lt) 2021-04-26
AU2014359276A1 (en) 2016-06-16
CA2932318A1 (en) 2015-06-11
DK3077519T3 (en) 2021-06-14
US10111945B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
IL276210A (en) MERS-COV vaccine
HK1226440A1 (zh) Cmv疫苗
IL279395A (en) A vaccine
HRP20181376T1 (hr) Poboljšana cjepiva protiv poksvirusa
EP3065716C0 (en) FORMULATIONS
AU356420S (en) Blower
GB201315946D0 (en) Oncology vaccine
ZA201508642B (en) Malaria vaccine
HK1218872A1 (zh) 乙型肝炎疫苗
GB201318084D0 (en) Malaria vaccination
GB201319792D0 (en) Formulations
HK1224228A1 (zh) 新型製劑
HK1214951A1 (zh) 眼用製劑
HK1217206A1 (zh) 疫苗
GB201315399D0 (en) Heater
GB201301119D0 (en) Viral vaccines
EP3034888A4 (en) BLOWER
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
GB201314063D0 (en) Virus
GB201312369D0 (en) Cm/hr
GB201306812D0 (en) Virus
GB201417087D0 (en) No detials
GB201311614D0 (en) Heater